Corcept Therapeutics Inc. Stock
The Corcept Therapeutics Inc. stock is trending slightly upwards today, with an increase of €0.32 (0.430%) compared to yesterday's price.
With 11 Buy predictions and not the single Sell prediction the community is currently very high on Corcept Therapeutics Inc..
With a target price of 124 € there is a hugely positive potential of 65.38% for Corcept Therapeutics Inc. compared to the current price of 74.98 €.
Our community identified positive and negative aspects for Corcept Therapeutics Inc. stock for the coming years. 0 users see the criterium "Worthwhile Investment for the next years" as a plus for the Corcept Therapeutics Inc. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Corcept Therapeutics Inc. in the next few years
Pros
?
M***** P*******
?
B****
?
C******** o* t** e**********
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Corcept Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Corcept Therapeutics Inc. | 0.430% | 1.407% | 10.786% | 39.316% | 50.532% | 235.031% | 260.481% |
| Pacira Pharmaceuticals | 1.900% | 4.902% | 4.902% | 14.439% | 15.676% | -49.528% | -53.275% |
| Rockwell Medical Inc. | -0.990% | -5.729% | -2.742% | -59.451% | -60.417% | -14.194% | -92.157% |
| Twist Bioscience Corp | -2.080% | -5.009% | -4.111% | -41.759% | -42.357% | 8.611% | -77.470% |
Comments
Corcept Therapeutics (NASDAQ:CORT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $145.00 price target on the stock.
Show more
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics (NASDAQ:CORT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $145.00 price target on the stock.
Show more
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics (NASDAQ:CORT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $145.00 price target on the stock.
Show more
Ratings data for CORT provided by MarketBeat